33 results on '"Edmundson, C"'
Search Results
2. Diagnosis and Management of Iliac Artery Endofibrosis: Results of a Delphi Consensus Study
- Author
-
Hinchliffe, R.J., D'Abate, F., Abraham, P., Alimi, Y., Beard, J., Bender, M., Björck, M., Edmundson, C., Fernandez Garcia, B., Cherry, K., Álvarez Fernández, L.J., Feugier, P., Lee, J., Palfreeman, R., Passfield, L., Peach, G., Ricco, J.-B., Rimpler, H., Roake, J., Rouviere, O., Schep, G., Spark, I., Schumacher, Y.O., and Zierler, R.E.
- Published
- 2016
- Full Text
- View/download PDF
3. Preliminary indications of the burden of COVID-19 among people who inject drugs in England and Northern Ireland and the impact on access to health and harm reduction services
- Author
-
Croxford, S., Emanuel, E., Ibitoye, A., Njoroge, J., Edmundson, C., Bardsley, M., Heinsbroek, E., Hope, V., and Phipps, E.
- Published
- 2021
- Full Text
- View/download PDF
4. Consumer Perception Towards the Enhanced Color of Atypical Dark-Cutting Beef by Nitrite-Embedded Packaging
- Author
-
Edmundson, C., primary, Cassens, A., additional, Mafi, G., additional, Stein, D., additional, Riggs, A., additional, VanOverbeke, D., additional, and Ramanathan, R., additional
- Published
- 2019
- Full Text
- View/download PDF
5. Non-Traumatic Lower Limb Vascular Complications in Endurance Athletes. Review of Literature
- Author
-
Ehsan, O, Darwish, A, Edmundson, C, Mills, V, and Al-Khaffaf, H
- Published
- 2004
- Full Text
- View/download PDF
6. Are there missed opportunities for vaccinating against hepatitis B among people who inject drugs in the UK?
- Author
-
Njoroge, J., primary, Hope, V.D., additional, O'Halloran, C., additional, Edmundson, C., additional, Glass, R, additional, Parry, J.V., additional, and Ncube, F., additional
- Published
- 2019
- Full Text
- View/download PDF
7. Secondary distribution of injecting equipment obtained from needle and syringe programmes by people injecting image and performance enhancing drugs: England and Wales, 2012-15
- Author
-
Glass, R, Hope, VD, Njoroge, J, Edmundson, C, Smith, J, McVeigh, J, Parry, J, Desai, M, Glass, R, Hope, VD, Njoroge, J, Edmundson, C, Smith, J, McVeigh, J, Parry, J, and Desai, M
- Abstract
Background People who inject image and performance enhancing drugs (IPEDs) are often the largest group using needle and syringe programmes (NSPs) in the UK. NSP providers report these clients repeatedly collecting large amounts of equipment for others. The extent of secondary distribution of injecting equipment is unknown. Methods Data from national surveillance of people injecting IPEDs were used. Participants completed a questionnaire and provided a dried-blood spot sample. Data from two biennial surveys was combined; repeat participants were excluded. Self-reported data was used to explore the extent of secondary distribution. Results Of the participants, 87% (467) reported NSP use; median age was 31 years; 98% were male. A third (34%, 157) reported collecting equipment for others. Of those collecting for others, 154 reported how many people they had collected for: 55% had collected for one person, 27% for 2-9 people, 5% for 10-19 and 13% for 20 or more (no difference by psychoactive drug use). Those vaccinated for hepatitis B were more likely (22% [15/68] vs 6% [5/86], p = 0.003), and those reporting redness/swelling at an injection site were less likely to collect equipment for at least 20 others (8% [8/106] vs 25% [12/48], p = 0.003). Overall, 154 people collected equipment for 639-1,569 people injecting IPEDs. Conclusions Secondary distribution of injecting equipment is common among those injecting IPEDs and using NSPs. Whilst not allowing for rotational collection within groups, our analysis suggests that many of those injecting IPEDs are not in direct contact with NSPs. Innovation approaches for harm reduction interventions are needed.
- Published
- 2018
8. Gender differences in the kinetics and kinematics of distance running: implications for footwear design
- Author
-
Sinclair, J., Greenhalgh, Andrew, Edmundson, C. J., Brooks, D., and Hobbs, S. J.
- Abstract
Interest in distance running amongst females has expanded rapidly. Although there are numerous health benefits associated with running, the occurrence of injury is well documented. Given the relative susceptibility of females to overuse running injuries, a key issue within the discipline of footwear biomechanics that has yet to be appropriately addressed is the specific demands of athletic footwear for females. The aim of this study was therefore to provide both a kinetic and 3-D kinematic comparison of male and female runners in order to determine the relative susceptibility of females to the proposed mechanisms of overuse injuries and whether based on this information, females require more specific footwear designs to meet their needs. Twelve male participants and twelve female participants completed five successful trials running at 4.0ms-1+5%. 3-D angular joint kinematics from the hip, knee and ankle were collected using an eight camera motion analysis system. In addition simultaneous tibial acceleration and ground reaction forces were obtained. Differences in impact parameters and joint kinematics were subsequently compared using independent samples t-tests. Females were found to be associated with significantly greater knee abduction, knee internal rotation and ankle eversion, whilst males were associated with significantly greater hip flexion. Based on these findings it is recommended that females select running footwear with design characteristics aimed towards the reduction of coronal plane ankle eversion in order to reduce the incidence of injury.
- Published
- 2012
9. Influence of the helical and six available Cardan sequences on 3D ankle joint kinematic parameters
- Author
-
Sinclair, J., primary, Taylor, P. J., additional, Edmundson, C. J., additional, Brooks, D., additional, and Hobbs, S. J., additional
- Published
- 2012
- Full Text
- View/download PDF
10. Organ Recitals
- Author
-
Edmundson, C. G. and Abram, Richard
- Published
- 1981
- Full Text
- View/download PDF
11. Determination of gait events using an externally mounted shank accelerometer
- Author
-
Sinclair, J., Sarah Jane Hobbs, Protheroe, L., Edmundson, C. J., and Greenhalgh, A.
12. The Impact of Direct-Acting Antivirals on Hepatitis C viraemia among people who inject drugs in England; real world data 2011-2018
- Author
-
Bardsley, M, Heinsbroek, E, Harris, R, Croxford, S, Edmundson, C, Hope, VD, Hassan, N, Ijaz, S, Mandal, S, Shute, J, Hutchinson, SJ, Hickman, M, Sinka, K, and Phipps, E
- Subjects
QR355 ,RA0421 ,RA ,QR - Abstract
Background: Direct-acting antiviral (DAA) therapy for anybody with viraemic HCV infection has been scaled-up in England since 2017. To assess early impacts, we described trends in, and factors associated with, HCV viraemia among people who inject drugs (PWID). We also examined trends in self-reported treatment access. Methods: Bio-behavioural data from an annual, national surveillance survey of PWID (2011 to 2018) estimated trends in viraemic prevalence among HCV antibody-positive PWID. Multivariable logistic regression identified characteristics independently associated with viraemia. Trends in treatment access were examined for PWID with known infection. Findings: Between 2011 and 2016, viraemic prevalence among antibody-positive PWID remained stable (2011, 57.7%; 2016, 55.8%) but decreased in 2017 (49.4%) and 2018 (50.4%) (both p
13. Are there missed opportunities for vaccinating against hepatitis B among people who inject drugs in the United Kingdom?
- Author
-
Njoroge, J, Hope, VD, O’Halloran, C, Edmundson, C, Glass, R, Parry, JV, and Ncube, F
- Subjects
RA0421 - Abstract
Sustaining the impact of hepatitis B virus (HBV) vaccination on incidence and prevalence of HBV infection requires increasing and maintaining the uptake of vaccine among those at risk. In recent years, the level of vaccine uptake among people who inject drugs (PWID) in the United Kingdom (UK) has levelled-off. Data (2015-16) from the national unlinked anonymous monitoring survey of PWID an annual survey that collects data from PWID across England, Wales and Northern Ireland was used to examine HBV vaccine uptake. Data from participants who had injected drugs during the previous year was used to investigate sources of hepatitis B vaccine doses as well as factors associated with vaccine uptake. Among the 3175 anti-HBc negative participants, 3138 (99%) reported their vaccination status; 23% (714) reported no vaccine uptake. Among those not vaccinated, 447 (63%) reported being sexually active and 116 (16%) reported sharing needles and syringes. Majority of those not vaccinated reported accessing services in the previous year that could have provided hepatitis B vaccine doses. These missed opportunities for vaccinating of PWID indicate a need for additional targeted interventions.
14. Letters.
- Author
-
Mako, Anthony A., Kebrle, John, George Jr., Truett, Welborn, Florence, Weber, Guenter, Miles, William O., Kemper, Guy, Nulman, David, Manetta, J. G., Doads, William F., and Edmundson, C. D. "Skip"
- Abstract
Several letters to the editor are presented in response to topics in previous issues including the International Competition and Exhibition of stained glass, the condition of the market of stained glass products and the idea of a technical and reference manual for stained glass.
- Published
- 1988
15. Development of a method to identify foot strike on an arena surface: application to jump landing.
- Author
-
Hobbs, S. J., Orlande, O., Edmundson, C. J., Northrop, A. J., and Martin, J. H.
- Subjects
- *
HORSES' injuries , *FOOT injuries , *HOOFS , *KINEMATICS , *JUMPING - Abstract
Foot strike can be difficult to determine using kinematics alone, particularly when studying equine activities on more compliant surfaces, so this study was done with the aim of developing and validating a method to determine foot strike on an arena surface that can be used in conjunction with kinematics alone, and of applying the method in the context of measuring foot strike during jump landing on an arena surface. A low-cost contact mat was developed. The timing of the contact mat switching 'on' was compared to the timing of a force platform onset of 20 N, load and loading rate at foot strike. Two groups of 25 participants were used in two separate studies to validate the contact mat: the first measured the difference in timing with respect to two different activities (running and stepping down from a box), and the second measured the difference in timing with respect to 1- and 2-cm depths of an arena surface during running. In a third study, the mat was used to measure leading limb foot strike of six horses during jump landing, and these data were compared to kinematics from a palmar marker on the hoof wall. All data were recorded at 500 Hz. A consistent difference in delay was found between the mat and force platform onset, and as a result, no significant differences (P > 0.05) in timing delay between different loading rates or depths were found. During jump landing, foot strike (determined from the mat) occurred after the vertical velocity minima and the acceleration maxima for the hoof marker, but it occurred before the point where the rate of vertical displacement began to reduce. In conclusion, further work is needed to enhance these techniques, but these preliminary results indicate that this method may be effective in determining foot strike for field-based applications. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
16. Has the HCV cascade of care changed among people who inject drugs in England since the introduction of direct-acting antivirals?
- Author
-
Gliddon HD, Ward Z, Heinsbroek E, Croxford S, Edmundson C, Hope VD, Simmons R, Mitchell H, Hickman M, Vickerman P, and Stone J
- Abstract
Background: In England, over 80 % of those with hepatitis C virus (HCV) infection have injected drugs. We quantified the HCV cascade of care (CoC) among people who inject drugs (PWID) in England and determined whether this improved after direct-acting antivirals (DAAs) were introduced., Methods: We analysed data from nine rounds of national annual cross-sectional surveys of PWID recruited from drug services (2011-2019; N = 12,320). Study rounds were grouped as: 'Pre-DAAs' (2011-2014), 'Prioritised DAAs' (2015-2016) and 'Unrestricted DAAs' (2017-2019). Participants were anonymously tested for HCV antibodies and RNA and completed a short survey. We assessed the proportion of PWID recently (current/previous year) tested for HCV. For participants ever HCV treatment eligible (past chronic infection with history of treatment or current chronic infection), we assessed the CoC as: HCV testing (ever), received a positive test result, seen a specialist nurse/doctor, and ever treated. We used logistic regression to determine if individuals progressed through the CoC differently depending on time-period, whether time-period was associated with recent testing (all participants) and lifetime HCV treatment (ever eligible participants), and predictors of HCV testing and treatment in the Unrestricted DAAs period., Results: The proportion of ever HCV treatment eligible PWID reporting lifetime HCV treatment increased from 12.5 % in the Pre-DAAs period to 25.6 % in the Unrestricted DAAs period (aOR:2.40, 95 %CI:1.95-2.96). There were also increases in seeing a specialist nurse/doctor. The largest loss in the CoC was at treatment for all time periods. During the Unrestricted DAAs period, recent (past year) homelessness (vs never, aOR:0.66, 95 %CI:0.45-0.97), duration of injecting (≤3 years vs >3 years; aOR:0.26, 95 %CI:0.12-0.60), never (vs current, aOR:0.31, 95 %CI:0.13-0.75) or previously being prescribed OAT (vs current, aOR:0.67, 95 %CI:0.47-0.95), and never using a NSP (vs past year, aOR:0.27, 95 %CI:0.08-0.89) were negatively associated with lifetime HCV treatment. The proportion of PWID reporting recent HCV testing was higher during Unrestricted DAAs (56 %) compared to Pre-DAAs (48 %; aOR:1.28, 95 %CI:1.06-1.54)., Conclusion: COC stages from seeing a specialist onwards improved after DAAs became widely available. Further improvements in HCV testing are needed to eliminate HCV in England., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 The Author(s). Published by Elsevier B.V. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
17. Recent increases in crack injection and associated risk factors among people who inject psychoactive drugs in England and Wales.
- Author
-
Edmundson C, Croxford S, Emanuel E, Njoroge J, Ijaz S, Hope V, Phipps E, and Desai M
- Abstract
Background: Crack use is higher in the United Kingdom (UK) than other European countries. Crack is a stimulant with a short half-life, requiring frequent injection to maintain its euphoric effects, thus increasing the risk of blood borne viruses (BBVs) and skin and soft tissue infections (SSTIs). We assessed trends in the prevalence of current crack injection among people who inject drugs (PWID) and investigated harms and other factors associated with its use., Methods: We used data from the annual Unlinked Anonymous Monitoring Survey of PWID, which recruits people who have ever injected psychoactive drugs through specialist services. Participants provide a biological sample and self-complete a questionnaire. We included participants from England and Wales who had injected in the past month. We examined trends in crack injection over time (2011-2021) and factors associated with crack injection using multivariable logistic regression (2019-2021)., Results: The proportion of people self-reporting crack injection in the past month almost doubled between 2011-2020/21, from 34 % (416/1237) to 57 % (483/850). Crack injection was more frequently reported by males than females (adjusted odds ratio 1.46, 95 % confidence interval: 1.15-1.87) and injected alongside heroin (6.67, 4.06-10.97) more frequently than alone. Crack injection was independently associated with injecting equipment sharing (1.64, 1.30-2.07), groin injection (2.03, 1.60-2.56) in the past month, overdosing in the past year (1.90, 1.42-2.53), homelessness in the past year (1.42, 1.14-1.77) and ever having hepatitis C infection (1.64, 1.31-2.06)., Conclusion: Crack injection has increased significantly over the past decade in England and Wales. People injecting crack are more likely to engage in behaviours that increase the risk of BBV and SSTI acquisition, such as needle/syringe sharing, groin injection and polydrug use. Harm reduction and drug treatment services should adapt to support the needs of this growing population of people injecting stimulants., Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2023. Published by Elsevier B.V.)
- Published
- 2023
- Full Text
- View/download PDF
18. Epidemiology of HIV infection and associated behaviours among people who inject drugs in England, Wales, and Northern Ireland: Nearly 40 years on.
- Author
-
Croxford S, Emanuel E, Shah A, Chau C, Hope V, Desai M, Ijaz S, Shute J, Edmundson C, Harris RJ, Delpech V, and Phipps E
- Subjects
- Humans, Male, Northern Ireland epidemiology, Risk-Taking, Wales epidemiology, Drug Users, HIV Infections complications, Substance Abuse, Intravenous complications, Substance Abuse, Intravenous epidemiology
- Abstract
Introduction: People who inject drugs are at high risk of blood-borne infections. We describe the epidemiology of HIV among people who inject drugs in England, Wales, and Northern Ireland (EW&NI) since 1981., Methods: National HIV surveillance data were used to describe trends in diagnoses (1981-2019), prevalence (1990-2019), and behaviours (1990-2019) among people who inject drugs aged ≥15 years in EW&NI. HIV care and treatment uptake were assessed among those attending in 2019., Results: Over the past four decades, the prevalence of HIV among people who inject drugs in EW&NI remained low (range: 0.64%-1.81%). Overall, 4978 people who inject drugs were diagnosed with HIV (3.2% of cases). Diagnoses peaked at 234 in 1987, decreasing to 78 in 2019; the majority were among white men born in the UK/Europe (90%), though the epidemic diversified over time. Late diagnosis (CD4 <350 cells/µl) was common (2010-2019: 52% [429/832]). Of those who last attended for HIV care in 2019, 97% (1503/1550) were receiving HIV treatment and 90% (1375/1520) had a suppressed viral load (<200 copies/ml). HIV testing uptake has steadily increased among people who inject drugs (32% since 1990). However, in 2019, 18% (246/1404) of those currently injecting reported never testing. The proportion of people currently injecting reporting sharing needles/syringes decreased from 1999 to 2012, before increasing to 20% (288/1426) in 2019, with sharing of any injecting equipment at 37% (523/1429)., Conclusion: The HIV epidemic among people who inject drugs in EW&NI has remained relatively contained compared with in other countries, most likely because of the prompt implementation of an effective national harm reduction programme. However, risk behaviours and varied access to preventive interventions among people who inject drugs indicate the potential for HIV outbreaks., (© 2022 Crown copyright. HIV Medicine published by John Wiley & Sons Ltd on behalf of British HIV Association. This article is published with the permission of the Controller of HMSO and the Queen’s Printer for Scotland.)
- Published
- 2022
- Full Text
- View/download PDF
19. The Effectiveness of Low Dead Space Syringes for Reducing the Risk of Hepatitis C Virus Acquisition Among People Who Inject Drugs: Findings From a National Survey in England, Wales, and Northern Ireland.
- Author
-
Trickey A, Croxford S, Emanuel E, Ijaz S, Hickman M, Kesten J, Thomas C, Edmundson C, Desai M, and Vickerman P
- Subjects
- Cross-Sectional Studies, England epidemiology, Hepacivirus, Humans, Northern Ireland epidemiology, RNA, Syringes, Wales epidemiology, Drug Users, HIV Infections complications, Hepatitis C complications, Hepatitis C epidemiology, Hepatitis C prevention & control, Substance Abuse, Intravenous complications
- Abstract
Syringes with attached needles (termed fixed low dead space syringes [LDSS]) retain less blood following injection than syringes with detachable needles, but evidence on them reducing blood-borne virus transmission among people who inject drugs (PWID) is lacking. Utilizing the UK Unlinked Anonymous Monitoring cross-sectional bio-behavioral surveys among PWID for 2016/18/19 (n = 1429), we showed that always using fixed LDSS was associated with 76% lower likelihood (adjusted odds ratio = 0.24, 95% confidence interval [CI]: .08-.67) of recent hepatitis C virus infection (RNA-positive and antibody-negative) among antibody-negative PWID compared to using any syringes with detachable needles., Competing Interests: Potential conflicts of interest. P. V. reports unrestricted research funding off Gilead unrelated to this work. M. H. reports personal fees from Gilead, Abbvie, and MSD as unrestricted speaker fees and support for travel in last 5 years and is Trustee of Society of Study of Addiction and Regional Editor of Addiction. C. T. reports funding awarded to the institution from the National Institute for Health Research Health Protection Research Unit in Behavioral Science and Evaluation and National Institute for Health Research Applied Collaboration West outside of the submitted work. P. V. reports grant made to institution from National Institute for Health Research Health Protection Research Unit in Behavioral Science and Evaluation outside of the submitted work. J. K. reports being partly funding by NIHR ARC West and NIHR HPRU in BSE via the University of Bristol for the current study. All other authors report no potential conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed., (© The Author(s) 2022. Published by Oxford University Press for the Infectious Diseases Society of America.)
- Published
- 2022
- Full Text
- View/download PDF
20. The impact of direct-acting antivirals on hepatitis C viraemia among people who inject drugs in England; real-world data 2011-2018.
- Author
-
Bardsley M, Heinsbroek E, Harris R, Croxford S, Edmundson C, Hope V, Hassan N, Ijaz S, Mandal S, Shute J, Hutchinson SJ, Hickman M, Sinka K, and Phipps E
- Subjects
- Antiviral Agents therapeutic use, Humans, Male, Prevalence, Viremia drug therapy, Viremia epidemiology, Hepatitis C drug therapy, Hepatitis C epidemiology, Hepatitis C, Chronic drug therapy, Pharmaceutical Preparations, Substance Abuse, Intravenous complications, Substance Abuse, Intravenous drug therapy, Substance Abuse, Intravenous epidemiology
- Abstract
Direct-acting antiviral (DAA) therapy for anybody with viraemic HCV infection has been scaled-up in England since 2017. To assess early impacts, we investigated trends in, and factors associated with, HCV viraemia among people who inject drugs (PWID). We also examined trends in self-reported treatment access. Bio-behavioural data from an annual, national surveillance survey of PWID (2011-2018) estimated trends in viraemic prevalence among HCV antibody-positive PWID. Multivariable logistic regression identified characteristics independently associated with viraemia. Trends in treatment access were examined for PWID with known infection. Between 2011 and 2016, viraemic prevalence among antibody-positive PWID remained stable (2011, 57.7%; 2016, 55.8%) but decreased in 2017 (49.4%) and 2018 (50.4%) (both p < 0.001). After adjustment for demographic and behavioural characteristics, there remained significant reduction in viraemia in 2017 (adjusted odds ratio [aOR] 0.79, 95% CI 0.65-0.94) and 2018 (aOR 0.79, 95% CI 0.66-0.93) compared to 2016. Other factors associated with viraemia were male gender (aOR 1.68, 95% CI 1.53-1.86), geographical region, injecting in past year (aOR 1.26, 95% CI 1.13-1.41), imprisonment (aOR 1.14, 95% CI 1.04-1.31) and homelessness (aOR 1.17, 95% CI 1.04-1.31). Among non-viraemic PWID with known infection, the proportion reporting ever receiving treatment increased in 2017 (28.7%, p < 0.001) and 2018 (38.9%, p < 0.001) compared to 2016 (14.5%). In conclusion, there has been a small reduction in HCV viraemia among antibody-positive PWID in England since 2016, alongside DAA scale-up, and some indication that treatment access has improved in the same period. Population-level monitoring and focus on harm reduction is critical for achieving and evaluating elimination., (© 2021 Crown copyright. Journal of Viral Hepatitis published by John Wiley & Sons Ltd. This article is published with the permission of the Controller of HMSO and the Queen's Printer for Scotland.)
- Published
- 2021
- Full Text
- View/download PDF
21. Letters to Lee: From Pearl Harbor to the War's Final Mission
- Author
-
EDMUNDSON, JAMES V., EDMUNDSON, CELIA, EDITED BY, EDMUNDSON, JAMES V., and EDMUNDSON, CELIA
- Published
- 2009
- Full Text
- View/download PDF
22. Post-vaccination HPV seroprevalence among female sexual health clinic attenders in England.
- Author
-
Mesher D, Thomas SL, Linley E, Edmundson C, Checchi M, Waterboer T, Bender N, Müller M, Beddows S, Borrow R, and Soldan K
- Subjects
- Adolescent, Adult, Case-Control Studies, England epidemiology, Female, Human papillomavirus 16, Human papillomavirus 18, Humans, Seroepidemiologic Studies, Vaccination, Young Adult, Papillomavirus Infections epidemiology, Papillomavirus Infections prevention & control, Papillomavirus Vaccines, Sexual Health
- Abstract
Background: The National HPV Immunisation Programme was introduced in England in September 2008 using the HPV16/18 bivalent vaccine. We conducted serological surveillance to explore vaccination coverage levels. We also conducted a case-control study to investigate a hypothesised cross-protective effect of the HPV16/18 vaccine against genital warts., Methods: Residual serum specimens from 16 to 20 year-old women attending six specialist sexual health services (SSHS) between 2011 and 2015 in England were tested for antibodies against HPV16 and HPV18 using a virus-like particle (VLP)-based multiplex serology assay. Patients were classified as having vaccine-induced seropositivity if they were seropositive for both HPV types and either had high antibody levels for at least one HPV type, or moderately high levels for both HPV types. Differences in vaccine-induced seropositivity by patient characteristics were investigated using logistic regression. Vaccine-induced seropositivity was then compared for patients with genital warts (cases) and matched patients without (controls)., Results: Of 3,973 serum specimens collected, 3,870 (97.4%) had a valid result. The proportion of women with vaccine-induced seropositivity decreased with age (from 78.1% in 16-year-olds to 52.6% in 20-year-olds). Vaccine-induced seropositivity was lower among women born outside the UK, from more deprived areas and with a history of chlamydia diagnosis. A difference in uptake by ethnic group was also seen but this was largely confounded by differences in deprivation and country of birth. Among 537 cases and 1,515 controls, there was little evidence of a protective effect of the bivalent HPV vaccine against genital warts (adjusted odds ratio 0.93; 95% CI: 0.74-1.18)., Discussion: Vaccine-induced seropositivity in this high-risk population was in line with vaccination coverage in the general population although was lower in some at-risk sub-groups. This study does not provide evidence to support a cross-protective effect of the HPV16/18 vaccine against genital warts., Competing Interests: Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: RB and EL perform contact research on behalf of Public Health England for GSK, Pfizer and Sanofi Pasteur. TW serves on advisory boards for Merck Sharp & Dohme (MSD). The Blood Safety, Hepatitis, Sexually Transmitted Infections (STI) and HIV Service has provided GSK with post-marketing surveillance reports on HPV infections; a cost recovery charge is made for these reports. All other authors have no further conflict of interests., (Crown Copyright © 2021. Published by Elsevier Ltd. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
23. Factors associated with hepatitis C and HIV testing uptake among men who inject image and performance enhancing drugs.
- Author
-
Hope VD, McVeigh J, Begley E, Glass R, Edmundson C, Heinsbroek E, Kean J, Campbell J, Whitfield M, Morgan G, Acreman D, and Smith J
- Subjects
- Adult, HIV Testing, Hepacivirus, Humans, Male, Prevalence, HIV Infections diagnosis, HIV Infections epidemiology, Hepatitis C epidemiology, Performance-Enhancing Substances, Substance Abuse, Intravenous epidemiology
- Abstract
Introduction and Aims: Historically, people who inject image and performance enhancing drugs (IPED) were not perceived as being at high risk of HIV or hepatitis C virus (HCV) infection. However, recent studies indicate HCV and HIV prevalences are elevated, with many HCV infections undiagnosed., Design and Methods: Men who inject IPEDs recruited from community settings and specialist services, including needle-syringe programs, across UK during 2016 self-completed a questionnaire. Multivariate analyses examined factors associated with HCV/HIV testing., Results: The participants' (n=562; 24% service recruited) median age was 31 years, 4% identified as gay or bisexual, 18% had ever been imprisoned and 6% had ever injected a psychoactive drug. Those community recruited more often reported sharing drugs vials (16% vs. 8%, P=0.021) and, among those with 2+ sexual partners, poor condom use (50% vs. 36%, P=0.063), than those service recruited. Overall, one-third had ever been tested for HCV (31%) and/or HIV (34%). Testing uptake was associated with other risk factors for HCV/HIV, being recruited through services and having received metabolic tests. Participants' motivations for using IPEDs were associated with recruitment setting and HIV/HCV testing uptake., Discussion and Conclusions: The majority were untested for HCV/HIV. HCV/HIV testing and risks were associated with recruitment through services. Previous needle and syringe program-based studies have potentially overestimated testing uptake and underestimated risk. Targeted interventions are needed, particularly for those not accessing services. The association between HCV/HIV testing uptake and receipt of metabolic tests suggests that developing a combined offer of these tests as part of health monitoring could improve uptake., (© 2020 Australasian Professional Society on Alcohol and other Drugs.)
- Published
- 2021
- Full Text
- View/download PDF
24. Factors associated with skin and soft tissue infections among people who inject drugs in the United Kingdom: A comparative examination of data from two surveys.
- Author
-
Doran J, Harris M, Hope VD, Wright T, Edmundson C, Sinka K, and Heinsbroek E
- Abstract
Background: People who inject drugs (PWID) are at high risk of injection-related skin and soft tissue infections (SSTI). If not treated promptly, these can lead to serious health complications, which are a considerable healthcare burden. Data from two community surveys, with different approaches, were used to assess SSTI prevalence and associated factors among PWID to inform intervention implementation., Methods: Data were analysed from two surveys, a national surveillance survey (n=2,874; 2017-18) of infections among PWID in the United Kingdom (UK) and an in-depth survey (n=455; 2018-19) of SSTI among PWID based in London, UK. Multivariable logistic regression models were constructed to ascertain the factors associated with self-reported SSTI., Results: High prevalence of SSTI were reported in both samples: 52 % of participants from the national surveillance survey reported having SSTI within the preceding 12 months and 65 % of the London sample reported a lifetime history of SSTI. The factors associated with SSTI in both surveys were similar, including older age; number of years injecting; number of attempts required to inject into the vein; injecting into the hands, feet, groin or neck and re-using or sharing needles/syringes., Conclusions: The number of PWID reporting SSTI in the UK is concerningly high. The two surveys used different recruitment approaches but found similar associations. We provide strong evidence of a relationship between venous access difficulty and SSTI. To stem the increase of SSTI and related complications in the UK, it is crucial that interventions attend to the underlying causes of venous damage among PWID., Competing Interests: Declaration of Competing Interest No conflict declared., (Copyright © 2020 Elsevier B.V. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF
25. Reliable and efficient scale to assess upper motor neuron disease burden in amyotrophic lateral sclerosis.
- Author
-
Quinn C, Edmundson C, Dahodwala N, and Elman L
- Subjects
- Aged, Amyotrophic Lateral Sclerosis physiopathology, Electrodiagnosis, Female, Humans, Male, Middle Aged, Reproducibility of Results, Severity of Illness Index, Amyotrophic Lateral Sclerosis diagnosis, Motor Neurons physiology
- Abstract
Background: Validation of biomarkers of upper motor neuron (UMN) impairment in amyotrophic lateral sclerosis (ALS) requires a reliable clinical assessment of UMN findings. The Penn Upper Motor Neuron Score© (PUMNS) is a standardized measure of UMN signs in ALS. Our aims were to evaluate its intra- and inter-rater reliability, and to examine inter-item reliability as a proxy for item relatedness and scale efficiency., Methods: Study procedures were performed during routine clinic visits. We calculated intra and inter-rater reliability using Pearson's correlation coefficient and inter-item reliability using Cronbach's alpha., Results: PUMNS had high intra and inter-rater reliability. Total and sub-score correlation coefficients were all ≥0.96. The inter-item reliability indicated appropriate item relatedness with reasonable efficiency and sub-score correlation coefficients between 0.68 and 0.85., Conclusions: PUMNS is a reliable measure of UMN signs in ALS and would be a useful tool in validating imaging and laboratory biomarkers of UMN injury in ALS., (© 2019 Wiley Periodicals, Inc.)
- Published
- 2020
- Full Text
- View/download PDF
26. Yield of next-generation neuropathy gene panels in axonal neuropathies.
- Author
-
Lee DC, Dankwa L, Edmundson C, Cornblath DR, and Scherer SS
- Subjects
- Adult, Aged, Aged, 80 and over, Female, High-Throughput Nucleotide Sequencing, Humans, Male, Middle Aged, Young Adult, Charcot-Marie-Tooth Disease genetics, Genetic Predisposition to Disease genetics
- Abstract
The use and utility of targeted gene panels for diagnosing the type of Charcot-Marie-Tooth have grown rapidly because commercial gene panels that contain most of the relevant genes are available and affordable for many patients. We used a targeted gene panel to analyze 175 patients who had an unexplained axonal polyneuropathy affecting large myelinated axons, 86 of whom reported a family history of neuropathy, and 89 of whom did not. In patients reporting a family history, the panel identified a pathogenic variant causing the neuropathy in six cases (7%); in patients not reporting a family history, the gene panel identified pathogenic variants causing neuropathy in two patients (2%). Interpretation in a tertiary referral setting, current gene panels identify the genetic cause of neuropathy in a small minority of patients who have an unexplained axonal neuropathy, even in those reporting a family history., (© 2019 Peripheral Nerve Society.)
- Published
- 2019
- Full Text
- View/download PDF
27. Eculizumab: A Complementary addition to existing long-term therapies for myasthenia gravis.
- Author
-
Edmundson C and Guidon AC
- Subjects
- Antibodies, Monoclonal, Humanized, Humans, Myasthenia Gravis
- Published
- 2019
- Full Text
- View/download PDF
28. Acute Manifestations of Neuromuscular Disease.
- Author
-
Edmundson C and Bird SJ
- Subjects
- Acute Disease, Humans, Emergencies, Neuromuscular Diseases complications, Neuromuscular Diseases diagnosis, Neuromuscular Diseases therapy
- Abstract
Neuromuscular emergencies may be defined as disorders or exacerbation of diseases of the peripheral nervous system that are rapidly progressive and potentially life-threatening. Such disorders can affect any level of the peripheral nervous system, from the muscle to the anterior horn cell. While their clinical manifestations may vary, severe morbidity and mortality is most frequently the result of neuromuscular respiratory failure. Some disorders, such as Guillain-Barré syndrome, provide the additional threat of severe, and potentially irreversible, nerve loss. Others, such as rhabdomyolysis and malignant hyperthermia, may produce serious medical complications. This article reviews neuromuscular emergencies by localization in the peripheral nervous system of the underlying disorder, as well as the identification and management of neuromuscular respiratory failure., Competing Interests: None., (Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.)
- Published
- 2019
- Full Text
- View/download PDF
29. Secondary distribution of injecting equipment obtained from needle and syringe programmes by people injecting image and performance enhancing drugs: England and Wales, 2012-15.
- Author
-
Glass R, Hope VD, Njoroge J, Edmundson C, Smith J, McVeigh J, Parry J, and Desai M
- Subjects
- Adult, Cross-Sectional Studies, England epidemiology, Female, Harm Reduction, Hepatitis B epidemiology, Hepatitis B prevention & control, Hepatitis B psychology, Humans, Male, Needle-Exchange Programs standards, Performance-Enhancing Substances adverse effects, Substance Abuse, Intravenous psychology, Substance Abuse, Intravenous therapy, Surveys and Questionnaires, Wales epidemiology, Body Image psychology, Needle-Exchange Programs methods, Performance-Enhancing Substances administration & dosage, Substance Abuse, Intravenous epidemiology, Syringes standards
- Abstract
Background: People who inject image and performance enhancing drugs (IPEDs) are often the largest group using needle and syringe programmes (NSPs) in the UK. NSP providers report these clients repeatedly collecting large amounts of equipment for others. The extent of secondary distribution of injecting equipment is unknown., Methods: Data from national surveillance of people injecting IPEDs were used. Participants completed a questionnaire and provided a dried-blood spot sample. Data from two biennial surveys was combined; repeat participants were excluded. Self-reported data was used to explore the extent of secondary distribution., Results: Of the participants, 87% (467) reported NSP use; median age was 31 years; 98% were male. A third (34%, 157) reported collecting equipment for others. Of those collecting for others, 154 reported how many people they had collected for: 55% had collected for one person, 27% for 2-9 people, 5% for 10-19 and 13% for 20 or more (no difference by psychoactive drug use). Those vaccinated for hepatitis B were more likely (22% [15/68] vs 6% [5/86], p = 0.003), and those reporting redness/swelling at an injection site were less likely to collect equipment for at least 20 others (8% [8/106] vs 25% [12/48], p = 0.003). Overall, 154 people collected equipment for 639-1569 people injecting IPEDs., Conclusions: Secondary distribution of injecting equipment is common among those injecting IPEDs and using NSPs. Whilst not allowing for rotational collection within groups, our analysis suggests that many of those injecting IPEDs are not in direct contact with NSPs. Innovation approaches for harm reduction interventions are needed., (Crown Copyright © 2019. Published by Elsevier B.V. All rights reserved.)
- Published
- 2019
- Full Text
- View/download PDF
30. The Impact of the National HPV Vaccination Program in England Using the Bivalent HPV Vaccine: Surveillance of Type-Specific HPV in Young Females, 2010-2016.
- Author
-
Mesher D, Panwar K, Thomas SL, Edmundson C, Choi YH, Beddows S, and Soldan K
- Subjects
- Adolescent, Age Distribution, DNA, Viral genetics, England epidemiology, Female, Humans, Mass Vaccination, Papillomaviridae genetics, Papillomaviridae isolation & purification, Papillomavirus Infections immunology, Papillomavirus Infections virology, Papillomavirus Vaccines immunology, Population Surveillance, Program Evaluation statistics & numerical data, Young Adult, Papillomaviridae classification, Papillomavirus Infections epidemiology, Papillomavirus Vaccines administration & dosage
- Abstract
Background: The national human papillomavirus (HPV) immunization program was introduced in England in September 2008 using the bivalent vaccine., Methods: We collected residual vulva-vaginal swab specimens from 16 to 24-year-old women attending for chlamydia screening between 2010 and 2016 and tested for HPV DNA. We compared changes in type-specific (vaccine and nonvaccine) HPV prevalence over time and association with vaccination coverage. For women with known vaccination status, vaccine effectiveness was estimated., Results: HPV DNA testing was completed for 15459 specimens. Prevalence of HPV16/18 decreased between 2010/2011 and 2016 from 8.2% to 1.6% in 16-18 year olds and from 14.0% to 1.6% in 19-21 year olds. Declines were also seen for HPV31/33/45 (6.5% to 0.6% for 16-18 year olds and 8.6% to 2.6% for 19-21 year olds). Vaccine effectiveness for HPV16/18 was 82.0% (95% confidence interval [CI], 60.6%-91.8%) and for HPV31/33/45 was 48.7% (95% CI, 20.8%-66.8%). Prevalence of HPV16/18 was compared to findings in 2007-2008 (prevaccination) and to predictions from Public Health England's mathematical model., Discussion: Eight years after the introduction of a national HPV vaccination program, substantial declines have occurred in HPV16/18 and HPV31/33/45. The prevalence of other high-risk HPV types has not changed.
- Published
- 2018
- Full Text
- View/download PDF
31. Patterns of injecting and non-injecting drug use by sexual behaviour in people who inject drugs attending services in England, Wales and Northern Ireland, 2013-2016.
- Author
-
Heinsbroek E, Glass R, Edmundson C, Hope V, and Desai M
- Subjects
- Adult, Cocaine pharmacology, England epidemiology, Female, Humans, Illicit Drugs pharmacology, Ketamine pharmacology, Male, Methadone pharmacology, Methamphetamine analogs & derivatives, Methamphetamine pharmacology, N-Methyl-3,4-methylenedioxyamphetamine pharmacology, Northern Ireland epidemiology, Sexual Behavior, Solvents pharmacology, Wales epidemiology, Young Adult, Heterosexuality psychology, Heterosexuality statistics & numerical data, Sexual and Gender Minorities psychology, Sexual and Gender Minorities statistics & numerical data, Substance Abuse, Intravenous epidemiology, Substance-Related Disorders epidemiology
- Abstract
Background: Higher levels of drug use have been reported in lesbian, gay, bisexual and transgender (LGBT) communities, some of which can be explained by sexualised drug use, including 'chemsex'; the use of drugs before or during planned sexual activity to sustain, enhance, disinhibit or facilitate sex. We explored injecting and non-injecting drug use by sexual behaviour among people who inject drugs (PWID) in England, Wales and Northern Ireland., Methods: Data were used from an unlinked-anonymous survey of PWID (2013-2016), where participants recruited through services self-completed a questionnaire. We included sexually active participants who had injected in the previous year, and compared injecting and non-injecting drug use between men reporting sex with men (MSM) and heterosexual men, and between women reporting sex with women (WSW) and heterosexual women. The questionnaire did not include GHB/GBL and methamphetamine use., Results: There were 299 MSM, 3215 heterosexual male, 122 WSW and 1336 heterosexual female participants. MSM were more likely than heterosexual men to use drugs associated with chemsex: injected or non-injected mephedrone (adjusted OR (AOR) 2.22, 95%CI 1.54-3.22; AOR 2.15, 95%CI 1.48-3.11) and injected or non-injected ketamine (AOR 1.98, 95%CI 1.29-3.05; AOR 2.57, 95%CI 1.59-4.15). MSM were also more likely to inject methadone, inhale solvents, take ecstasy, cocaine or speed. WSW were more likely than heterosexual women to use non-injected mephedrone (AOR 2.19, 95%CI 1.20-3.99) and use injected or non-injected ketamine (AOR 5.58, 95%CI 2.74-11.4; AOR 3.05, 95%CI 1.30-7.19). WSW were also more likely to inject methadone, inject cocaine, use non-injected cocaine, crack, benzodiazepines or ecstasy, inhale solvents, or smoke cannabis., Conclusion: Injecting and non-injecting drug use differed between MSM/WSW and heterosexual men and women. The use of drugs that have been associated with chemsex and sexualised drug use is more common among both MSM and WSW than heterosexual men and women., (Copyright © 2018. Published by Elsevier B.V.)
- Published
- 2018
- Full Text
- View/download PDF
32. Sexualised drug use in the United Kingdom (UK): A review of the literature.
- Author
-
Edmundson C, Heinsbroek E, Glass R, Hope V, Mohammed H, White M, and Desai M
- Subjects
- Humans, United Kingdom epidemiology, 4-Butyrolactone pharmacology, Illicit Drugs pharmacology, Methamphetamine analogs & derivatives, Methamphetamine pharmacology, Sexual and Gender Minorities statistics & numerical data, Sodium Oxybate pharmacology, Substance-Related Disorders epidemiology, Unsafe Sex drug effects
- Abstract
Background: Sexualised drug use (SDU) refers to the use of drugs in a sexual context. This includes 'Chemsex'- the use of drugs (specifically crystal methamphetamine, GHB/GBL and mephedrone) before or during planned sexual activity to sustain, enhance, disinhibit or facilitate the experience. Here we aimed to synthesise available UK prevalence data for Chemsex, SDU and the use of Chemsex drugs in an undefined context (CDU) in men who have sex with men (MSM)., Methods: Papers published between January 2007 and August 2017 reporting Chemsex, SDU and/or Chemsex drug use (CDU) prevalence in MSM were identified through PubMed. Citations were searched for further eligible publications. We also conducted a review of national surveillance data, extracting prevalence data for Chemsex, SDU or CDU. Synthesized data were then assessed to determine the time at which these drugs were taken, in this case just prior to or during sexual activity (event-level)., Results: Our search identified 136 publications, of which 28 were included in the final data synthesis. Three of the four surveillance systems assessed provided SDU or CDU data in MSM. Few publications included event-level data for Chemsex (n = 4), with prevalence estimates ranging from 17% among MSM attending sexual health clinics (SHC) to 31% in HIV-positive MSM inpatients. Prevalence estimates for SDU (n = 7 publications) also varied considerably between 4% in MSM receiving HIV care to 41% among MSM attending SHC for HIV post-exposure prophylaxis (PEP). Eighteen publications provided data for CDU., Conclusion: Prevalence estimates varied considerably due to differences in the definition used and population assessed. Standardised definitions and studies with representative national samples of MSM are required to improve our understanding of the extent of Chemsex and its associated risks. Longitudinal event-level data for SDU and Chemsex are needed to monitor impact of interventions., (Crown Copyright © 2018. Published by Elsevier B.V. All rights reserved.)
- Published
- 2018
- Full Text
- View/download PDF
33. Neuromuscular Disorders in Pregnancy.
- Author
-
Edmundson C and Guidon AC
- Subjects
- Female, Humans, Pregnancy, Motor Neuron Disease complications, Motor Neuron Disease drug therapy, Motor Neuron Disease immunology, Motor Neuron Disease physiopathology, Muscular Diseases complications, Muscular Diseases drug therapy, Muscular Diseases immunology, Muscular Diseases physiopathology, Myasthenia Gravis complications, Myasthenia Gravis drug therapy, Myasthenia Gravis immunology, Myasthenia Gravis physiopathology, Peripheral Nervous System Diseases complications, Peripheral Nervous System Diseases drug therapy, Peripheral Nervous System Diseases immunology, Peripheral Nervous System Diseases physiopathology, Pregnancy Complications drug therapy, Pregnancy Complications immunology, Pregnancy Complications physiopathology
- Abstract
Neuromuscular disorders may present and progress differently in women than in men. During pregnancy, medication adjustment, hormonal effects, and other alterations in physiology may influence the manifestation of a variety of neuromuscular disorders. The expression of existing conditions may change; previously asymptomatic conditions may be unmasked, or entirely new conditions may develop. Additionally, neuromuscular disorders and their treatments may have implications for the fetus. Such factors must be carefully considered when counseling and treating pregnant women and those considering pregnancy. This article reviews considerations specific to women and issues surrounding pregnancy in disorders of the neuromuscular junction, focal neuropathies, and acquired and inherited disorders of the nerve and muscle., Competing Interests: Conflict of Interest: None., (Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.)
- Published
- 2017
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.